In Brief: DuPont Merck/Avid DMP450
Executive Summary
DuPont Merck/Avid DMP450: DuPont Merck licenses worldwide marketing rights to DMP450, a second generation HIV protease inhibitor, to Avid for an upfront payment of $1.75 mil., $14 mil. in future milestones and 5% royalty fees. Camden, N.J.-based Avid intends to initiate Phase I/II clinical trials in next few months...